Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

NCT03377023 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT03377023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03377023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 2, 2018
Completion date
August 31, 2026
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nonsmall cell, non small cell lung cancer, non small cell lung cancer metastatic